Treatment patterns and clinical outcomes of tyrosine kinase inhibitors in chronic-phase CML in clinical practice: 3-year European SIMPLICITY data
| Autor: | Christy Guyan, Mauricette Michallet, Rüdiger Hehlmann, Catherine Davis, Ronald Paquette, Carlo Gambacorti-Passerini, Clara Chen, Ginny P Sen, Stuart L. Goldberg |
|---|---|
| Přispěvatelé: | Gambacorti Passerini, C, Chen, C, Davis, C, Sen, G, Guyan, C, Hehlmann, R, Michallet, M, Paquette, R, Goldberg, S |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
Myeloid observational studie 0302 clinical medicine MED/15 - MALATTIE DEL SANGUE imatinib mesylate dasatinib Practice Patterns Physicians' Aged 80 and over leukemia Disease Management Myeloid leukemia Hematology General Medicine Middle Aged Prognosis Europe Dasatinib chronic Leukemia Treatment Outcome medicine.anatomical_structure 030220 oncology & carcinogenesis Leukemia Myeloid Chronic-Phase Cohort Female Original Article myeloid Tyrosine kinase medicine.drug Adult medicine.medical_specialty Clinical Decision-Making 03 medical and health sciences Internal medicine medicine Humans Protein Kinase Inhibitors observational studies BCR‐ABL positive chronic-phase Aged BCR-ABL positive business.industry chronic‐phase Original Articles medicine.disease respiratory tract diseases Imatinib mesylate Observational study business Follow-Up Studies 030215 immunology |
| Zdroj: | European Journal of Haematology |
| Popis: | Objectives: SIMPLICITY (NCT01244750) is an observational study of patients with chronic-phase chronic myeloid leukemia (CP-CML) in routine clinical practice receiving first-line tyrosine kinase inhibitors (TKIs). We evaluated TKI treatment changes and how switching affects clinical response in patients recruited in Europe with ≥3years of follow-up. Methods: The SIMPLICITY European cohort (France, Germany, Italy, the Netherlands, Russia, and Spain) included 431 patients. 370 (86%) were followed for ≥3years. Results: Proportions of patients experiencing treatment interruptions, TKI switching, and discontinuations decreased over 3years’ follow-up. Intolerance was a key driver for treatment changes. Complete cytogenetic response (CCyR) was achieved in 87.5% of patients switching TKI within 3years of initiation vs 91.7% of non-switchers. Major molecular response (MMR) was achieved in 82.4% of switchers vs 92.9% of non-switchers. Over 3years, not switching TKI was a strong predictor for achieving CCyR or MMR (both P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|